Clene Nanomedicine, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public, Subsidiary

Established: 2013-01-01

Employees: 51

Market Cap: -

Website: http://www.clene.com

Clinical Trials

Intermediate Expanded Access Protocol CNMAu8.EAP04

Conditions: ALS
Amyotrophic Lateral Sclerosis
PALS

First Posted Date: 2024-05-10

Last Posted Date: 2024-07-31

Lead Sponsor: Clene Nanomedicine

Registration Number: NCT06408727

Locations: 🇺🇸
Texas Neurology, Dallas, Texas, United States
🇺🇸
Synapticure, Chicago, Illinois, United States
🇺🇸
Pennsylvania State University, Hershey, Pennsylvania, United States

and more 2 locations

An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS

Phase 2

Active, not recruiting

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: CNMAu8

First Posted Date: 2022-03-29

Last Posted Date: 2024-07-19

Lead Sponsor: Clene Nanomedicine

Target Recruit Count: 40

Registration Number: NCT05299658

Locations: 🇦🇺
Neuroscience Research Australia, Randwick, New South Wales, Australia
🇦🇺
Concord Hospital, Concord, New South Wales, Australia

Two Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01 and CNMAu8.EAP02 for ALS

Conditions: Amyotrophic Lateral Sclerosis

First Posted Date: 2022-03-16

Last Posted Date: 2024-08-02

Lead Sponsor: Clene Nanomedicine

Registration Number: NCT05281484

Locations: 🇺🇸
Penn State Health (Enrollment is full, not recruiting), Hershey, Pennsylvania, United States
🇺🇸
Texas Neurology, Dallas, Texas, United States
🇺🇸
Nova Southeastern University, Davie, Florida, United States

and more 14 locations

A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis

Phase 2

Completed

Conditions: Relapsing Multiple Sclerosis

Interventions: Drug: CNM-Au8

First Posted Date: 2020-11-13

Last Posted Date: 2023-12-08

Lead Sponsor: Clene Nanomedicine

Target Recruit Count: 55

Registration Number: NCT04626921

Locations: 🇦🇺
Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
🇦🇺
Menzies Institute for Medical Research, Hobart, TAZ, Australia
🇦🇺
Sydney Brain Mind Centre, Camperdown, New South Wales, Australia

and more 2 locations

Study of ZnAg Liquid Solution to Treat COVID-19 Symptomatic Participants

Phase 2

Completed

Conditions: Covid19

Interventions: Drug: CNM-ZnAg
Drug: Placebo

First Posted Date: 2020-10-30

Last Posted Date: 2023-04-03

Lead Sponsor: Clene Nanomedicine

Target Recruit Count: 296

Registration Number: NCT04610138

Locations: 🇧🇷
IBPClin, Gloria, Rio De Janeiro, Brazil
🇧🇷
Projeto Praca Onze, Centro, Rio De Janeiro, Brazil
🇧🇷
PROCAPE, Santo Amaro, Recife, Brazil

and more 2 locations

Therapeutic Nanocatalysis to Slow Disease Progression of Amyotrophic Lateral Sclerosis (ALS)

Phase 2

Completed

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Placebo
Drug: CNM-Au8

First Posted Date: 2019-09-23

Last Posted Date: 2024-07-03

Lead Sponsor: Clene Nanomedicine

Target Recruit Count: 45

Registration Number: NCT04098406

Locations: 🇦🇺
Westmead Hospital, Sydney, New South Wales, Australia
🇦🇺
University of Sydney Brain and Mind Centre, Sydney, New South Wales, Australia

Intermediate Expanded Access Protocol CNMAu8.EAP03

Conditions: Multiple Sclerosis

First Posted Date: 2019-09-09

Last Posted Date: 2024-07-23

Lead Sponsor: Clene Nanomedicine

Registration Number: NCT04081714

Locations: 🇺🇸
University of Texas Southwestern, Dallas, Texas, United States

31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Multiple Sclerosis.

Phase 2

Recruiting

Conditions: Multiple Sclerosis

Interventions: Drug: gold nanocrystals

First Posted Date: 2019-06-20

Last Posted Date: 2024-05-08

Lead Sponsor: Clene Nanomedicine

Target Recruit Count: 30

Registration Number: NCT03993171

Locations: 🇺🇸
University of Texas Southwestern, Dallas, Texas, United States

31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Amyotrophic Lateral Sclerosis (REPAIR-ALS)

Phase 2

Withdrawn

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Gold Nanocrystals

First Posted Date: 2019-02-18

Last Posted Date: 2023-04-03

Lead Sponsor: Clene Nanomedicine

Registration Number: NCT03843710

Locations: 🇺🇸
UT Southwestern, Dallas, Texas, United States

31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Parkinson's Disease

Phase 2

Completed

Conditions: Parkinson's Disease

Interventions: Drug: Gold Nanocrystals

First Posted Date: 2019-01-24

Last Posted Date: 2024-05-16

Lead Sponsor: Clene Nanomedicine

Target Recruit Count: 13

Registration Number: NCT03815916

Locations: 🇺🇸
UT Southwestern, Dallas, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy